Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

Form 4	ONCOLOGY	Y INC									
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue Section 17(a) of the Publ				ECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549 HANGES IN BENEFICIAL OWNERSHIP O SECURITIES tion 16(a) of the Securities Exchange Act of 1934 dic Utility Holding Company Act of 1935 or Sec the Investment Company Act of 1940					Number: 3235-0287 Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5		
(Print or Type F	Responses)										
Lafond Kevin G Symbol			r Name and Ticker or Trading ARM ONCOLOGY INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	(First) ARM ONCOL FIRST AVEN .DG 34		3. Date of (Month/D 12/30/20	-	ansaction			Director X Officer (give below) Vice Pres		Owner er (specify CAO	
BOSTON, N	(Street) 4. If Amer Filed(Mon BOSTON, MA 02129				-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	12/30/2016			Code V A	Amount 39,300 (1)	(D) A	Price \$ 0	(Instr. 3 and 4) 67,300	D		
Common Stock	12/31/2016			F	9,333 (2)	D	\$ 5.35	57,967	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Title Amou Under Securi (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships							
	Director	10% Owner	Officer	Other					
Lafond Kevin G C/O ZIOPHARM ONCOLOGY, INC. ONE FIRST AVENUE, PARRIS BLDG 3 BOSTON, MA 02129	34		Vice Pres., Treasurer & CAO						
Signatures									
/s/ Caesar J. Belbel, Attorney-in-Fact	01/04/2017								
**Signature of Reporting Person	Date								

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 13,100 shares shall vest on each of 12/30/2017, 12/30/2018 and 12/30/2019.

(2) Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.